1. Estimating differential latent variable graphical models with applications to brain connectivity. (4th September 2020) Authors: Na, S; Kolar, M; Koyejo, O Journal: Biometrika Issue: Volume 108:Number 2(2021) Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P044 A novel porcine model of Crohn's disease anastomotic stricture. (25th January 2019) Authors: Lukas, M; Kolar, M; Ryska, O; Juhas, S; Juhasova, J; Kalvach, J; Pazin, J; Hadac, J; Vitkova, I; Bortlik, M; Lukas, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience. (30th January 2023) Authors: Kolar, M; Kastylova, K; Lukas, M; Duricova, D; Hruba, V; Machkova, N; Cerna, K; Jirsa, J; Kubickova, K; Vojtechova, G; Lukás, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P487 Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease. (25th January 2019) Authors: Pudilova, K; Kolar, M; Duricova, D; Malickova, K; Hruba, V; Machkova, N; Vanickova, R; Mitrova, K; Lukas, M; Vasatko, M; Lukas, M; Bortlik, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab. (16th January 2018) Authors: Kolar, M; Duricova, D; Bortlik, M; Lukas, M; Hruba, V; Machkova, N; Malickova, K; Lukas, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P641 Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn's disease. (25th January 2019) Authors: Kolar, M; Pudilova, K; Bortlik, M; Duricova, D; Malickova, K; Lukas, M; Hruba, V; Machkova, N; Vanickova, R; Mitrova, K; Vasatko, M; Lukas, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. (6th January 2020) Authors: Lukas, Martin; Malickova, K; Kolar, M; Bortlik, M; Vasatko, M; Machkova, N; Hruba, V; Duricova, D; Lukas, Milan Journal: Journal of Crohn's and colitis Issue: Volume 14:Number 7(2020) Page Start: 915 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗